2023
Bleeding pattern and consumption of factor VIII concentrate in adult patients with haemophilia A without inhibitors in the Czech Republic between 2013 and 2021 (Czech National Haemophilia Programme registry data)
ROMANOVÁ, Gabriela, Petr SMEJKAL, Petra OVESNÁ, Eva DRBOHLAVOVA, Petr DULICEK et. al.Základní údaje
Originální název
Bleeding pattern and consumption of factor VIII concentrate in adult patients with haemophilia A without inhibitors in the Czech Republic between 2013 and 2021 (Czech National Haemophilia Programme registry data)
Autoři
ROMANOVÁ, Gabriela (203 Česká republika, domácí), Petr SMEJKAL (203 Česká republika, domácí), Petra OVESNÁ (203 Česká republika), Eva DRBOHLAVOVA (203 Česká republika), Petr DULICEK (203 Česká republika), Zdenka HAJSMANOVA (203 Česká republika), Antonin HLUSI (203 Česká republika), Radka HRDLICKOVA (203 Česká republika), Jana ULLRYCHOVA (203 Česká republika), Ivan VONKE (203 Česká republika), Jan BLATNÝ (203 Česká republika, domácí), Zuzana CERMAKOVA (203 Česká republika), Ester ZAPOTOCKA (203 Česká republika) a Miroslav PENKA (203 Česká republika, domácí)
Vydání
Annals of hematology, New York, Springer Verlag, 2023, 0939-5555
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30205 Hematology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.500 v roce 2022
Kód RIV
RIV/00216224:14110/23:00132991
Organizační jednotka
Lékařská fakulta
UT WoS
001071705000001
Klíčová slova anglicky
Haemophilia; Bleeding; Prophylaxis; On-demand; Consumption of factor VIII/IX concentrate; CNHP (the Czech National Haemophilia Programme); EHL (extended half-life)
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 12. 1. 2024 14:45, Mgr. Tereza Miškechová
Anotace
V originále
The manuscript provides an overview of treatment and its changes in adult patients with haemophilia A without inhibitors in the Czech Republic between 2013 and 2021 using data from the registry of the Czech National Haemophilia Programme (CNHP). Over a 9-year period, we focused on the reduction in the annual bleeding rate (ABR), joint bleeding rate (AJBR) and factor VIII consumption when patients with severe haemophilia A switched from on-demand treatment to prophylaxis. The ABR and AJBR include both patient-reported home treatment and treated hospitalisation episodes. All adult patients with severe haemophilia A were categorised into three groups according to the therapeutic regimen. The first group was patients on prophylaxis during the follow-up period, the second group consisted of patients on on-demand treatment, and the third group was patients who received both treatment regimens during follow-up. With an increase in the proportion of patients with severe haemophilia A on prophylaxis from 37 to 74% between 2013 and 2021, the ABR for all patients with severe haemophilia A decreased approximately 6.9-fold, and the AJBR decreased 8.7-fold. Expectedly, the factor consumption increased by approximately 68.5%. In the group of patients with severe haemophilia A who had switched from an on-demand to a prophylactic regimen, the total number of bleeding events decreased 3.5-fold, and the number of joint bleeding episodes decreased 3.9-fold. Factor VIII consumption increased by 78.4%. Our study supports a previously reported positive effect of prophylaxis on bleeding control. We believe that the substantial improvement in ABR justifies the increased treatment costs.